Name
ALX Oncology
Company Description
ALX Oncology (Nasdaq: ALXO), is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives. Our lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. ALX Oncology announced positive data of evorpacept in combination with trastuzumab, ramucirumab, and paclitaxel in advanced HER2+ gastric cancer. Evorpacept is currently being evaluated in 9 clinical trials across solid tumors and hematologic cancers.
Website
Product Categories (5)
Breast Cancer, Gastrointestinal (Colorectal) Cancer, Genitourinary Cancer, Head and Neck Cancer, Hematologic Cancers
First Time Exhibitor
Yes
Address
South San Francisco, CA
United States
United States
Badges
